Baxter International Inc.

BAX trades at an 11.48% short float—notably elevated for a medical device company—while the RSI at 44.6 sits comfortably in neutral territory, suggesting neither oversold desperation nor overbought euphoria. The absence of a P/E ratio hints at either recent unprofitability or accounting peculiarities, raising questions about underlying operational health. With the stock nowhere near its 52-week highs despite a $8.9B market cap, there's a disconnect worth investigating: the elevated short interest combined with valuation ambiguity could either signal genuine fundamental weakness that shorts are front-running, or a contrarian setup where consensus pessimism has become overdone. The neutral RSI provides no directional clue, making this a company where fundamentals matter far more than technicals.